Immunologists want IL-6 inhibitors such as tocilizumab (Actemra) to be made available for off-label use in treatment of severe COVID-19 disease. While early clinical trials are still exploring the effects of the drug on severe inflammatory responses in COVID-19 disease, the Australasian Society for Clinical Immunology and Allergy (ASCIA) says its use should also be ...
Immunologists want tocilizumab for off-label use in COVID-19
By Michael Woodhead
28 Apr 2020